Skip to main content
. 2004 May;11(3):312–317. doi: 10.1101/lm.72804

Figure 3.

Figure 3

(A) Time latency during IA retention test. Groups with posttraining infusion of saline administered into the BLA and saline infused into the IC (SAL-SAL, n = 14), infusions of saline into the BLA and 8-Br-cAMP into the IC (SAL-8Br, n = 13), propranolol infusions of the BLA and saline infusions of the IC (PROP-SAL, n = 11), propranolol into the BLA and 8-Br-cAMP into the IC (PROP-8Br, n = 10; P < 0.01), saline infused into the BLA and oxotremorine into the IC (SAL-OXO, n = 6), and propranolol into the BLA and 0.6 μg of oxotremorine into the IC (PROP-OXO, n = 11). *P < 0.01 versus SAL-SAL, °P < 0.05 versus PROP-8Br or PROP-OXO. The shaded box inside SAL-SAL group indicates the entrance latency of the SAL-SAL group during the training day (mean, 17.43). (Paired t-test training versus test latency, t value = -2.14; P = 0.05). (B) Saccharine consumption on the CTA retention test for control (SAL-SAL, n = 17), saline infused into the BLA and 8-Br-cAMP into the IC (SAL-8Br, n = 19), propranolol into the BLA and saline into the IC (PROP-SAL, n = 13), and propranolol into the BLA and 8-Br-cAMP into the IC (PROP-8Br, n = 15). *P < 0.01 versus SAL-SAL group; °P < 0.05 versus SAL-8-Br group.